ontamalimab: Clinical Trials

10 trials of ontamalimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated, 4 completed. 7 Phase 3, 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 37Terminated 5, Completed 2
Phase 22Completed 2
Phase 11Terminated 1

Follow ontamalimab: new trials by email Literature Review of ontamalimab trials Research Report on ontamalimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
Ontamalimab - Steatohepatitis
Phase 1TerminatedTakeda112023-01-182025-08-19
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Ontamalimab, Placebo - Crohn's Disease
Phase 3TerminatedShire402019-02-062022-03-31
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Ontamalimab, Placebo - Crohn's Disease
Phase 3TerminatedShire302018-08-292021-04-29
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Ontamalimab, Placebo - Crohn's Disease
Phase 3TerminatedShire342018-07-172021-05-11
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ontamalimab, Placebo - Ulcerative Colitis
Phase 3CompletedShire3662018-04-042022-01-14
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
25 mg Ontamalimab, 75 mg Ontamalimab - Crohn's Disease, Ulcerative Colitis
Phase 3CompletedShire5572018-02-272024-06-21
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ontamalimab, Placebo - Ulcerative Colitis
Phase 3TerminatedShire3802018-02-092021-06-14
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ontamalimab, Placebo - Ulcerative Colitis
Phase 3TerminatedShire2792017-12-052021-04-26
Long-Term Safety Of PF-00547659 In Ulcerative Colitis
75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659) - Ulcerative Colitis
Phase 2CompletedShire3302013-03-182021-06-03
A Study To Monitor Long-Term Treatment With PF-00547659
PF-00547659 - Crohn's Disease
Phase 2CompletedShire2682011-07-012021-06-03

Conditions studied

Colitis, Ulcerative (5)  ·  Crohn Disease (5)  ·  Fatty Liver (1)  ·  Gastroenteritis (1)

Sponsors

Shire (9)  ·  Takeda (1)

Countries

United States (10)  ·  Japan (8)  ·  Austria (7)  ·  Belgium (7)  ·  Germany (7)  ·  Netherlands (7)  ·  Poland (7)  ·  Serbia (7)  ·  Slovakia (7)  ·  South Africa (7)  ·  South Korea (7)  ·  Spain (7)  ·  Australia (6)  ·  Bulgaria (6)  ·  Hungary (6)

Results publications

PMID 38096402, PMID 34427633

NIH funding

2017 (5)